Business
Braeburn Pharmaceuticals and Knight Therapeutics Announce Filing of New Drug Submission for PROBUPHINE® in Canada for Opioid Drug Dependence
Braeburn Pharmaceuticals and Knight Therapeutics Announce Filing of New Drug Submission fo...
About this update from Knight Therapeutics, Inc.
[{"type":"text","content":"\n\n\n\nBraeburn Pharmaceuticals and Knight Therapeutics Announce Filing of New Drug Submission for PROBUPHINE® in Canada for Opioid Drug Dependence\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nPRINCETON, N.J. and MONTREAL, June 13, 2017\n\n\n\n\n \n\n\nPRINCETON, N.J. and MONTREAL, June 13, 2017 /CNW/ -- Braeburn Pharmaceuticals, Inc. (\"Braeburn\") and Knight Therapeutics Inc. (TSX: GUD) (\"Knight\"), a leading Canadian specialty pharmaceutical company, announced today that Knight's New Drug Submission (NDS) has been accepted for review by Health Canada for Probuphine® (buprenorphine) implant for the treatment of opioid drug dependence. \n\n \n\n\n\n\"Probuphine is a unique and innovative product that has the potential to address an important unmet need for opioid dependent patients in Canada,\" said Jonathan Ross Goodman, Chief Executive Officer (CEO) of Knight. \"With Probuphine, Knight is continuing to advance its portfolio of opioid supportive therapeutics, which includes Movantik®, a product for opioid-induced constipation we in-licensed from AstraZeneca and began commercializing in March of this year.\"\n\n\"Opioid addiction is an overwhelming public health epidemic in North America. Acceptance of the NDS in Canada is another important milestone for Probuphine,\" said Mike Derkacz, President and CEO of Braeburn. \n\n\"We look forward to working with Knight and Health Canada to bring this important treatment option to Canadian patients.\"\n\nKnight and Braeburn signed an exclusive distribution and sublicense agreement in February 2016, granting Knight the exclusive right to distribute Probuphine in Canada. \n\nAbout PROBUPHINE®Probuphine is the only subdermal implant designed to deliver buprenorphine continuously for six months following a single treatment.\n\nProbuphine was developed using ProNeura™, the continuous drug delivery system developed by Titan Pharmaceuticals, Inc. (\"Titan\") that consists of a small, solid implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The result...